Small molecule regulation of normal and leukemic stem cells

Current Opinion in Hematology

Volumn 22, Issue 4, 2015, Pages 309-316

  Fares, Iman ^a   Rivest Khan, Laura ^a   Cohen, Sandra ^b   Sauvageau, Guy ^a,b,c  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Hematopoietic stem cell; Leukemic stem cell; Self renewal; Small molecules

Indexed keywords

CD34 ANTIGEN; CD45RA ANTIGEN; CHEMICAL COMPOUND; CYTOKINE; NICOTINAMIDE; PROSTAGLANDIN E2; SHEMREGENIN 1; SITAGLIPTIN; UM 171; UNCLASSIFIED DRUG; VALPROIC ACID; AROMATIC HYDROCARBON RECEPTOR; INDOLE DERIVATIVE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEMREGENIN 1; UM171 COMPOUND;

CANCER STEM CELL; CELL HOMING; CELL RENEWAL; CYTOKINE PRODUCTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH THROUGHPUT SCREENING; LEUKEMIC STEM CELL; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; CELL COUNT; CELL PROLIFERATION; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECTS; FETUS BLOOD; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LEUKEMIA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

CELL COUNT; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; FETAL BLOOD; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDOLES; LEUKEMIA; NEOPLASTIC STEM CELLS; PURINES; PYRIMIDINES; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION;

EID: 84942811534     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000151     Document Type: Review

References (41)

1. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study (COBLT) : Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008; 112: 4318-4327.
2. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: Relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693-4699.
3. Ramirez P, Brunstein CG, Miller B, et al. Delayed platelet recovery after allogeneic transplantation: A predictor of increased treatment-related mortality and poorer survival. Bone Marrow Transplant 2011; 46: 981-986.
4. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-2285.
5. Cheung AM, Nguyen LV, Carles A, et al. Analysis of the clonal growth and differentiation dynamics of primitive barcoded human cord blood cells in NSG mice. Blood 2013; 122: 3129-3137.
6. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: A human perspective. Cell Stem Cell 2012; 10: 120-136.
7. Notta F, Doulatov S, Laurenti E, et al. Isolation of single human hematopoietic stem cells capable of long-Term multilineage engraftment. Science 2011; 333: 218-221.
8. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-743.
9. Shpall EJ, Quinones R, Giller R, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002; 8: 368-376.
10. Csaszar E, Kirouac DC, Yu M, et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. Cell Stem Cell 2012; 10: 218-229.
11. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367: 2305-2315.
12. Chattopadhyay S, Stewart AL, Mukherjee S, et al. Niche-based screening in multiple myeloma identifies a kinesin-5 inhibitor with improved selectivity over hematopoietic progenitors. Cell Rep 2015; 10: 755-770.
13. Ito S, Barrett AJ, Dutra A, et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res 2015; 14: 95-104.
14. Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232-236.
15. Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010; 329: 1345-1348.
16. North TE, Goessling W, Walkley CR, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007; 447: 1007-1011.
17. Hoggatt J, Singh P, Sampath J, Pelus LM. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009; 113: 5444-5455.
18. Goessling W, Allen RS, Guan X, et al. Prostaglandin E2 enhances human cord blood stemcell xenotransplants and shows long-Term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 2011; 8: 445-458.
19. + or lineage-human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-Term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev 2007; 16: 355-360.
20. + cells and increases their engraftment potential in NOD/SCID mice. Exp Hematol 2004; 32: 547-555.
21. Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol 2012; 40: 342.e1-355.e1.
22. Chaurasia P, Gajzer DC, Schaniel C, et al. Epigenetic reprogramming induces the expansion of cord blood stem cells. J Clin Invest 2014; 124: 2378-2395.
23. Fares I, Chagraoui J, Gareau Y, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 2014; 345: 1509-1512.
24. Frisch BJ, Porter RL, Gigliotti BJ, et al. In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands shortterm hematopoietic stem cells. Blood 2009; 114: 4054-4063.
25. Goessling W, North TE, Loewer S, et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009; 136: 1136-1147.
26. Cutler C, Multani P, Robbins D, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013; 122: 3074-3081.
27. Farag SS, Srivastava S, Messina-Graham S, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev 2013; 22: 1007-1015.
28. de Lima M, McMannis J, Gee A, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: A phase I/II clinical trial. Bone Marrow Transplant 2008; 41: 771-778.
29. Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-Term multilineage engraftment. J Clin Invest 2014; 124: 3121-3128.
30. Zhang CC, Lodish HF. Cytokines regulating hematopoietic stem cell function. Curr Opin Hematol 2008; 15: 307-311.
31. Milpied N, Dazey B, Ivanovic Z, et al. Rapid and sustained engraftment of a single allogeneic ex-vivo expanded cord blood unit (CBU) after reduced intensity conditioning (RIC) in adults. Preliminary Results of a Prospective Trial. Blood (ASH Annual Meeting Abstracts) 2011, 118 (Abstract 486).
32. Ivanovic Z, Duchez P, Chevaleyre J, et al. Clinical-scale cultures of cord blood CD34 (+) cells to amplify committed progenitors and maintain stem cell activity. Cell Transplant 2011; 20: 1453-1463.
33. Bouchez LC, Boitano AE, de Lichtervelde L, et al. Small-molecule regulators of human stem cell self-renewal. Chembiochem 2011; 12: 854-857.
34. Chen X, Skutt-Kakaria K, Davison J, et al. G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev 2012; 26: 2499-2511.
35. Al-Hussaini M, DiPersio JF. Small molecule inhibitors in acute myeloid leukemia: From the bench to the clinic. Expert Rev Hematol 2014; 7: 439-464.
36. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822.
37. Notta F, Mullighan CG, Wang JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469: 362-367.
38. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.
39. Pabst C, Krosl J, Fares I, et al. Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat Methods 2014; 11: 436-442.
40. Stubbs MC, Armstrong SA. Therapeutic implications of leukemia stem cell development. Clin Cancer Res 2007; 13: 3439-3442.
41. Davies SG, Kennewell PD, Russell AJ, et al. Stemistry: The control of stem cells in situ using chemistry. J Med Chem 2015; 28: 2863-2894.